A Phase 1b dose escalation study with a Phase 2a expansion component to evaluate the safety and tolerability of ETC 1907206 in combination with dasatinib in advance hematologic malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
D3-005

Phase of Trial
Phase 1b/2a

To Learn More Call
(201)-510-0950